4 Healthcare Stock Stories Closing Out June Trading

Sanofi-Aventis (NYSE: SNY): Closing price $51.51

The Sanofi company Genzyme said Friday that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for approval of Lemtrada (alemtuzumab) for the treatment of adult patients suffering from relapsing remitting multiple sclerosis, with active disease defined by clinical or imaging features. Beyond that, the Committee released a positive opinion on new active substance designation for Aubagio (teriflunomide). Earlier in 2013, the Committee issued a positive opinion recommending the clearance of Aubagio for the treatment of adult patients with relapsing remitting MS.

Are these stocks a buy or sell? Let us help you decide. SNY

More Articles About:   , , ,